The 36-month beta value for SGMO is also noteworthy at 1.47. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for SGMO is 214.59M, and at present, short sellers hold a 12.35% of that float. The average trading volume of SGMO on March 24, 2025 was 5.94M shares.
SGMO) stock’s latest price update
The stock of Sangamo Therapeutics Inc (NASDAQ: SGMO) has increased by 6.22 when compared to last closing price of 0.87.Despite this, the company has seen a loss of -8.86% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-17 that Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie – Vice President, Investor Relations and Corporate Communications Sandy Macrae – Chief Executive Officer Nathalie Dubois-Stringfellow – Chief Development Officer Prathyusha Duraibabu – Chief Financial Officer Conference Call Participants Luis Santos – H.C. Wainwright Maury Raycroft – Jefferies Nicole Germino – Truist Gena Wang – Barclays Operator Good afternoon, and welcome to the Sangamo Therapeutics Fourth Quarter and Full Year 2024 Teleconference Call.
SGMO’s Market Performance
Sangamo Therapeutics Inc (SGMO) has experienced a -8.86% fall in stock performance for the past week, with a -13.97% drop in the past month, and a -60.83% drop in the past quarter. The volatility ratio for the week is 9.48%, and the volatility levels for the past 30 days are at 11.26% for SGMO. The simple moving average for the past 20 days is -2.29% for SGMO’s stock, with a -20.59% simple moving average for the past 200 days.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with Truist repeating the rating for SGMO by listing it as a “Buy.” The predicted price for SGMO in the upcoming period, according to Truist is $7 based on the research report published on December 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $10. The rating they have provided for SGMO stocks is “Buy” according to the report published on December 10th, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to SGMO, setting the target price at $2 in the report published on November 03rd of the previous year.
SGMO Trading at -13.46% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.04% of loss for the given period.
Volatility was left at 11.26%, however, over the last 30 days, the volatility rate increased by 9.48%, as shares sank -8.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.54% lower at present.
During the last 5 trading sessions, SGMO fell by -9.23%, which changed the moving average for the period of 200-days by +61.52% in comparison to the 20-day moving average, which settled at $0.9418. In addition, Sangamo Therapeutics Inc saw -9.75% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -1.69 for the present operating margin
- 0.91 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -1.69. The total capital return value is set at -1.75. Equity return is now at value -187.83, with -73.33 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -2.2.
Currently, EBITDA for the company is -89.09 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 3.32. The receivables turnover for the company is 12.57for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.13.
Conclusion
In summary, Sangamo Therapeutics Inc (SGMO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
